AnalystBook Research · Company Intelligence

ASTRAZENECA PLC

AZNNYSE

Built from ASTRAZENECA PLC's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 20-F · headline figures audited against SEC data

Revenue grew 8.6% to $58.74B and net income rose 45.3% to $10.22B, led by oncology medicines.

The read at a glance✓ Audited against SEC data
  • Growth — Revenue +8.6% to $58.74B; oncology product sales $23,698mOK
  • Profitability — Operating margin 23.4%, up 490 bps; net income $10.22BOK
  • Cash — Free cash flow $11.77B, +18.4%OK
  • Accounting — Grey-zone Altman-Z; no manipulation flag; earnings quality safeNote
  • Capital — Dividends $4.97B, +7.4%; no buybacksNote
  • Medicines — Soliris sales fell to $1,837m and Brilinta to $823m as copies arrivedWatch

Business

AstraZeneca is a UK-based drug maker whose largest business is cancer medicines. Oncology product sales were $23,698m of $55,573m in 2025, ahead of cardiovascular, renal and metabolism, respiratory and immunology, and rare disease medicines. The US is its largest market at $23,444m of product sales, followed by the emerging markets at $15,056m.

Latest filings

  • 6-K · Company announcement (foreign filer)2026-10-02
  • 6-K · Company announcement (foreign filer)2026-10-01
  • 6-K · Company announcement (foreign filer)2026-10-01
  • 6-K · Company announcement (foreign filer)2026-09-29
  • 6-K · Company announcement (foreign filer)2026-09-23
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about ASTRAZENECA PLC, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full AZN record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.